Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19

Abstract

This report, the third update of a previously published living systematic review (1), focuses on treatment (not prophylaxis) of coronavirus disease 2019 (COVID-19) with hydroxychloroquine or chloroquine. The first and second updates covered evidence available through 1 July 2020 (2) and 1 August 2020 (3), respectively. This update evaluates evidence published through 21 September 2020.No new evidence about chloroquine was found. One new randomized trial (4) and 5 new cohort studies (5-9) evaluating hydroxychloroquine were found. None of the studies used zinc; all studies (5-8) except for 1 (9) with a hydroxychloroquine group and an azithromycin group evaluated hydroxychloroquine alone. The trial used a "standard care" control group (4) and had high risk of bias, whereas all of the cohort studies had serious risk of bias (5-9). The trial (4) and 3 of the new cohort studies (6, 7, 9) assessed hospital-initiated hydroxychloroquine, whereas 2 of the new cohort studies (5, 8) assessed prehospital initiation.The Supplement Table displays the following for outcomes of all identified trials (4, 10 -16, 32, 34) and cohort studies (5-9, 17-31, 33, 35) that addressed treatment with hydroxychloroquine: risk-of-bias assessments, unadjusted estimates of effect, and overall ratings of strength of evidence. In trials, when hydroxychloroquine is initiated in the outpatient setting, there is low strength of evidence that it reduces hospitalizations (11, 12); whereas, in cohort studies, there remains insufficient evidence (5, 8, 33). There is now low strength of evidence that hydroxychloroquine has no positive effect on all-cause mortality and need for mechanical ventilation in both trials and cohort studies. Even with 3 new cohort studies assessing intensive care unit admission (5, 6, 8) and 1 trial (4) and 1 cohort study (9) assessing symptom resolution, there is still insufficient evidence for determining hydroxychloroquine's effect on both outcomes. No new trial or studies assessed any other outcome.It is becoming increasingly unlikely that in-hospital use of hydroxychloroquine will yield beneficial effects. The large SOLIDARITY-WHO and ORCHID-NIH trials have been prematurely discontinued, with press releases citing lack of efficacy (36, 37), but preprints or publications of these trials are still not available. However, the outpatient use of hydroxychloroquine is more promising. Trials with some concern of bias (11) and high risk of bias (12) found nonsignificant reductions in hospitalizations, whereas 2 cohort studies with serious risk of bias found significant reductions (5, 8). However, 1 cohort study with critical risk of bias found a significant increase (33). One of these cohort studies (5) found a significant reduction in intensive care unit admission with hydroxychloroquine use, whereas another found a nonsignificant reduction (8), which is in contrast to 2 cohort studies (6, 24) with serious risk of bias assessing inpatient use of hydroxychloroquine where intensive care unit admissions were significantly increased.

Perceptions of Romanian Physicians on Lockdowns for COVID-19 Prevention

“…Hydroxychloroquine was also considered in COVID-19 treatment because of previous research on SARS-CoV infection in 2002, as well as results regarding its in vitro inhibitory effects on SARS-CoV-2 replication [ 53 , 54 ]. However, hydroxychloroquine did not show significant benefits to standard care in COVID-19 [ 55 ] according to research including five randomized control trials [ 56 ]; moreover, hydroxychloroquine-related side effects were considered [ 57 ]. The hydroxychloroquine recommendation for COVID-19 treatment was, therefore, stopped [ 58 ].…”

COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development

“…85 A third update published on December 1 of a previously published living systematic review that focused on treatment of COVID-19 with hydroxychloroquine has concluded that it is becoming increasingly unlikely that in-hospital use of hydroxychloroquine will yield beneficial effects. 86 However, it reports that the outpatient use of hydroxychloroquine is promising. 86 Many antiviral agents have been developed against viral proteases, polymerases, MTases, and entry proteins.…”

“…86 However, it reports that the outpatient use of hydroxychloroquine is promising. 86 Many antiviral agents have been developed against viral proteases, polymerases, MTases, and entry proteins. Remdesivir (GS-5734) is a mono-phosphoramidate prodrug of an adenosine analog, which can incorporate nascent viral RNA and inhibit the RNA-dependent RNA polymerase.…”

Pandemia de COVID-19 en el Perú: ¿Qué hicimos y qué pudimos hacer mejor?

“…2 De esta manera, reconocemos el esfuerzo inicial del MINSA por incentivar su uso como prueba diagnóstica, debiendo abandonar dicho uso ahora y, obviamente, la compra de dichas pruebas, salvo para fines de estudios epidemiológicos. El Ministerio de Salud (MINSA) es el ente rector y emitió numerosas directivas en este tiempo de pandemia [3][4][5][6][7][8][9][10][11] , cuya implementación en un sistema de salud dividido parece haber sido una tarea difícil. Queda avanzar en el cumplimiento de estas normativas y actualizarlas de acuerdo con la evidencia científica.…”

“…Un tema importante es el relacionado a los recursos humanos. Reconocemos el esfuerzo por la protección y el cuidado del personal de salud 11 ; sin embargo, creemos que no fue acertado normar que el personal de salud mayor de 60 años dejara de trabajar, aun no teniendo comorbilidades. Luego una modificación dispensando solo a los mayores de 65 años.…”